Your session is about to expire
← Back to Search
Antimalarial
Combination Prevention Therapy for COVID-19 (HELPCOVID-19 Trial)
Phase 2
Waitlist Available
Led By Sabine Hazan, MD
Research Sponsored by ProgenaBiome
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Must not have
Type I or II diabetes
Any contraindication for treatment with hydroxychloroquine including: Hypoglycemia, G6PD deficiency, Porphyria, Anemia, Neutropenia, Alcoholism, Myasthenia Gravis, Skeletal muscle disorder, Maculopathy, Changes in the visual field, Liver disease, with ALT/AST > 2.5 upper limit normal and total bilirubin >2.5 upper limit normal, Psoriasis, Any contraindicated medications found in Appendix 2, Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject, Vaccination for SARS-CoV-2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Summary
This trial is testing whether a combination of hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19.
Who is the study for?
This trial is for adults over 18 who are at high risk of COVID-19 exposure, like healthcare workers. Participants must use two effective birth control methods if applicable and give informed consent. It's not for those with diabetes, previous COVID-19 infection, symptoms of the virus, certain heart diseases or conditions that hydroxychloroquine could worsen.
What is being tested?
The study is testing if a combination of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent COVID-19 symptoms in people at high risk of exposure. This Phase II trial aims to see how effective these treatments are together.
What are the potential side effects?
Potential side effects may include digestive issues due to vitamins and minerals; hydroxychloroquine might cause vision changes or muscle weakness among others. The exact side effects will be monitored throughout the study.
Eligibility Criteria
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have Type I or II diabetes.
Select...
I do not have health conditions that react badly to hydroxychloroquine.
Select...
I am showing symptoms of COVID-19.
Select...
I have been diagnosed with heart artery blockage.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Prevention of COVID-19 symptoms as recorded in a daily diary
Safety as determined by presence or absence of Adverse Events and Serious Adverse Events
Side effects data
From 2016 Phase 3 trial • 217 Patients • NCT0205725013%
Upper respiratory tract infection
6%
Neutropenia
6%
Sinusitis
5%
Alanine aminotransferase increased
5%
Urinary tract infection
4%
Injection site erythema
4%
Accidental overdose
4%
Bronchitis
3%
Injection site pruritus
2%
Thrombocytopenia
2%
Nasopharyngitis
2%
Contusion
1%
Arthralgia
1%
Wolff-Parkinson-White syndrome
1%
Coronary artery occlusion
1%
Anaemia
1%
Leukopenia
1%
Lumbar spinal stenosis
1%
Transient ischaemic attack
1%
Vertebrobasilar insufficiency
1%
Chronic obstructive pulmonary disease
1%
Small intestinal obstruction
1%
Nephrolithiasis
1%
Cataract
1%
Thrombophlebitis superficial
1%
Vomiting
1%
Endometrial hyperplasia
1%
Traumatic arthritis
1%
Hypertension
1%
Pneumonia
1%
Pancreatic carcinoma metastatic
1%
Osteoarthritis
1%
Rheumatoid lung
1%
Pharyngitis
1%
Femoral neck fracture
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sarilumab 150 mg by PFS (Extension Phase)
Sarilumab 150 mg by AID (AID Assessment Phase)
Sarilumab 150 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by PFS (AID Assessment Phase)
Sarilumab 200 mg by AID (AID Assessment Phase)
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Medical WorkersExperimental Treatment4 Interventions
Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.
Group II: PlaceboPlacebo Group3 Interventions
Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vitamin D
2013
Completed Phase 4
~3670
Vitamin C
2017
Completed Phase 4
~18470
Zinc
2005
Completed Phase 4
~16490
Hydroxychloroquine
FDA approved
Find a Location
Who is running the clinical trial?
ProgenaBiomeLead Sponsor
45 Previous Clinical Trials
4,750 Total Patients Enrolled
DSCS CROIndustry Sponsor
2 Previous Clinical Trials
136 Total Patients Enrolled
Sabine Hazan, MDPrincipal InvestigatorProgenaBiome
40 Previous Clinical Trials
4,429 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have experienced diarrhea before starting treatment.You have tested positive for COVID-19 before.I am over 18 and work in healthcare, making me high-risk.I have Type I or II diabetes.I do not have health conditions that react badly to hydroxychloroquine.I am showing symptoms of COVID-19.I have been diagnosed with heart artery blockage.
Research Study Groups:
This trial has the following groups:- Group 1: Medical Workers
- Group 2: Placebo
Awards:
This trial has 2 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger